JP2021175391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021175391A5 JP2021175391A5 JP2021056390A JP2021056390A JP2021175391A5 JP 2021175391 A5 JP2021175391 A5 JP 2021175391A5 JP 2021056390 A JP2021056390 A JP 2021056390A JP 2021056390 A JP2021056390 A JP 2021056390A JP 2021175391 A5 JP2021175391 A5 JP 2021175391A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 112
- 125000003275 alpha amino acid group Chemical group 0.000 claims 57
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 241000024188 Andala Species 0.000 claims 4
- 102000010956 Glypican Human genes 0.000 claims 4
- 108050001154 Glypican Proteins 0.000 claims 4
- 108050007237 Glypican-3 Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020062357 | 2020-03-31 | ||
| JP2020062357 | 2020-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021175391A JP2021175391A (ja) | 2021-11-04 |
| JP2021175391A5 true JP2021175391A5 (https=) | 2024-04-03 |
Family
ID=77928944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021056390A Pending JP2021175391A (ja) | 2020-03-31 | 2021-03-30 | 免疫活性化多重特異性抗原結合分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230147840A1 (https=) |
| EP (1) | EP4126958A4 (https=) |
| JP (1) | JP2021175391A (https=) |
| KR (1) | KR20220161156A (https=) |
| CN (1) | CN115315447A (https=) |
| AR (1) | AR121692A1 (https=) |
| SG (1) | SG11202105566TA (https=) |
| TW (1) | TW202204410A (https=) |
| WO (1) | WO2021200896A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| KR102813659B1 (ko) | 2013-11-11 | 2025-05-28 | 추가이 세이야쿠 가부시키가이샤 | 개변된 항체 가변영역을 포함하는 항원 결합 분자 |
| TWI831044B (zh) | 2014-11-11 | 2024-02-01 | 日商中外製藥股份有限公司 | 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法 |
| TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| US12590133B2 (en) | 2018-06-01 | 2026-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| KR20240082403A (ko) * | 2021-10-07 | 2024-06-10 | 내셔날 리서치 카운실 오브 캐나다 | 항-bcma 단일 도메인 항체 및 치료 작제물 |
| EP4413044A4 (en) * | 2021-10-07 | 2025-10-22 | Nat Res Council Canada | ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS |
| TW202540161A (zh) * | 2023-11-21 | 2025-10-16 | 美商健生生物科技公司 | 治療骨髓增生性腫瘤之方法 |
| WO2025210181A1 (en) * | 2024-04-04 | 2025-10-09 | Cdr-Life Ag | Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide |
| WO2025226541A2 (en) * | 2024-04-26 | 2025-10-30 | Janssen Biotech, Inc. | Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TW201938194A (zh) * | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| BR112021005722A2 (pt) * | 2018-09-28 | 2021-07-06 | Chugai Pharmaceutical Co Ltd | moléculas de ligação ao antígeno capazes de ligar cd3 e cd137, porém não simultaneamente |
| US12509524B2 (en) * | 2018-09-28 | 2025-12-30 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
-
2021
- 2021-03-30 TW TW110111557A patent/TW202204410A/zh unknown
- 2021-03-30 WO PCT/JP2021/013456 patent/WO2021200896A1/en not_active Ceased
- 2021-03-30 US US17/914,855 patent/US20230147840A1/en active Pending
- 2021-03-30 CN CN202180020903.4A patent/CN115315447A/zh not_active Withdrawn
- 2021-03-30 KR KR1020217031417A patent/KR20220161156A/ko not_active Withdrawn
- 2021-03-30 AR ARP210100788A patent/AR121692A1/es unknown
- 2021-03-30 SG SG11202105566TA patent/SG11202105566TA/en unknown
- 2021-03-30 EP EP21780692.6A patent/EP4126958A4/en not_active Withdrawn
- 2021-03-30 JP JP2021056390A patent/JP2021175391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021175391A5 (https=) | ||
| TWI585104B (zh) | 基於vl和vhh可變區衍生物的高親和力抗聚集抗體 | |
| JP2022031784A5 (https=) | ||
| JP7031810B2 (ja) | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 | |
| FI3802598T3 (fi) | Dll3/cd3:a sitovia proteiineja syövän hoitamiseksi | |
| CN115715202A (zh) | 抗体药物缀合物及其制备方法和用途 | |
| JP2022009816A5 (https=) | ||
| US11987609B2 (en) | Proteinaceous heterodimer and use thereof | |
| CN118063619A (zh) | 工程化的异源二聚体蛋白质 | |
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2021513366A (ja) | 抗ｐｄ−１／抗ｈｅｒ２天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法 | |
| JP2022051553A5 (https=) | ||
| JP2022537823A (ja) | 共有結合型多重特異性抗体 | |
| WO2021168194A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2025504909A5 (https=) | ||
| CN114127117A (zh) | 用于偶联的多肽复合物及其应用 | |
| JP2024507693A5 (https=) | ||
| WO2024131949A1 (zh) | Anti-cMet抗体、抗体药物偶联物及其制备方法和用途 | |
| JP2021522793A5 (https=) | ||
| WO2020192648A1 (en) | Proteinaceous heterodimer and use thereof | |
| CN112159473A (zh) | 重组人源化抗人白介素23单克隆抗体的纯化方法 | |
| CN108290942A (zh) | 与人及小鼠信号素3a交联的抗体及其用途 | |
| CN118754989A (zh) | 一种抗her2纳米抗体及其制备方法和应用 | |
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| CN120659804A (zh) | 多价蛋白质及筛选方法 |